key: cord-0877999-n4ds60sb
authors: nan
title: From the IASLC Tobacco Control Committee
date: 2020-10-31
journal: Journal of Thoracic Oncology
DOI: 10.1016/j.jtho.2020.08.010
sha: 09e3129e25dd7987f118d462618c6b7813588edb
doc_id: 877999
cord_uid: n4ds60sb

nan

Longitudinal evaluation of the impact of standardized packaging and minimum excise tax on tobacco sales and industry revenue in the UK This was the first study to assess effects on tobacco sales volume and company revenues from standardized packaging and minimum excise tax (MET) that were fully implemented in the UK in May 2017. UK commercial supermarket and convenience store electronic point of sale data on tobacco sales were analyzed, comparing a 10month period (June 2015-March 2016) before the transition to standardized packs with a 10-month period after the introduction of the MET and full implementation of standardized packs (June 2017-March 2018). The findings showed that concurrent introduction of standardized packaging and MET in the UK was associated with significant decline in sales (by average 6.4 million sticks monthly, almost twice that of prelegislation) and in tobacco industry revenues (monthly net revenues from £231 million to £198 million). It also indicated the end of the previous growth in cheap cigarette brands that appeal to young and price conscious smokers. To create an evidence-based guideline that addresses routine pharmacotherapy-initiation questions, a panel of diverse expertise related to smoking cessation conducted systematic reviews that informed recommendation, and used the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach to rate the certainty in the estimated effects and the strength of recommendations. As a result, seven recommendations regarding pharmacotherapy choices were provided. Five of them are strong recommendations, which include using varenicline rather than a nicotine patch, using varenicline rather than bupropion, using varenicline rather than a nicotine patch in adults with a comorbid psychiatric condition, initiating varenicline in adults even if they are unready to quit, and using controller therapy for an extended treatment duration greater than 12 weeks. Two conditional recommendations include combining a nicotine patch with varenicline rather than using varenicline alone and using varenicline rather than electronic cigarettes. 

In COVID-19, we may all be learning a little more about public health. There are daily cases, cases per million, doubling times, 7-day rolling averages and R values. Primary schoolers know about 'flattening the curve' as well as quarantine times and community transmission. Public health initiatives like hand hygiene and social distancing, the latter once unimaginable, are normal now. Ageing billboard advertisements that feature groups of people, unmasked and laughing, come from another planet. Movie scenes with crowds look strange. The countries with the best public health systems e quarantine, containment, contact tracing and testing e have kept their caseload down. Other countries are struggling. When public health works well, there is no spectacle, there are no avengers (although there are masks) and no series of explosions to herald success. The victories in public health usually come quietly, detected only when a problem fails to appear. In COVID-19 it is easier to focus on the dramatic images, the healthcare workers in PPE and long lines of ambulances, than on banks of contact tracers sitting by the phone. In tobacco control, it is easier to focus on the new, on e-cigarettes and vaping, than on the FCTC (Framework Convention on Tobacco Control)(1) and MPOWER measures(2) that have slowly and surely pushed down smoking rates over the last 50 years. Our Australian committee members have alerted us to a recent webinar entitled "Smoking: maintaining attention on a critical and unsolved public health problem" (3) . This webinar presented the findings from papers based upon the 45 and Up study(4), a study of healthy ageing in a quarter of a million people recruited from 2006 to 2009. In line with international data, a 2015 paper from this study showed that current smokers suffer (5) . Compared with never smokers, current smokers lose about 10 years of life with around 2/3 of them dying from the effects of smoking. The intensity of smoking also matters. Those who smoked more than 25 cigarettes per day had a four-fold mortality risk ratio compared with never smokers. Those who smoked more lightly (around 10 cigarettes per day) had a two-fold increase in mortality. Former smokers reduced their mortality risk almost from the minute they quit and if they could do so by age 45, could match that of never smokers. These mortality findings line up with international data (6)(7)(8)(9) and give clinicians, if so inclined, real impetus to work on smoking cessation as well as some statistical oomph. Further analysis of cardiovascular risk from this cohort confirms an across-the-board effect of smoking for a wide range of conditions (10) . A 2019 paper showed that over a third of cardiovascular disease deaths and a quarter of acute coronary syndrome presentations are related to smoking. These statistics, simple and profound, can be folded into clinical consultations about risk, adding to the urgency of the matter and, importantly giving current smokers something tangible to consider. Maybe we can use new public health skills, acquired from COVID-19, to help people quit smoking.

Efforts to control tobacco have been going on for a long time, more than twice the lifetimes of the current generation of young people who are at risk of taking up smoking. It can be easy to lose your way in the maze. In one direction there is regulation of old products, in the other there are attractive new products and the map is muddled by contradictions such as government ownership of tobacco companies, confusing messages about risk and deliberate misinformation from the tobacco industry. A recent paper helps put this mess into historical context in the USA, charting the development of tobacco control from the mid-20 th century realisation of the evolving disaster(11) until now. The paper opens its case with punchy statistics. More than 10 times as many Americans have been killed by cigarette smoking than by involvement in war, any war. The prevalence of smoking in the US has fallen by two thirds since the 1964 US Surgeon General Report (12) confirmed at federal level, the toxic effect of cigarette smoke. The paper points out that much of this reduction has come from lower "entry" rates (fewer young people taking up smoking) rather than better quit rates and divided the history of tobacco control into 4 main eras [We supplied the dates e Ed.]: A. Invention and marketing (c1900-1950); B. Discovery of Harm (c1950-64); C. Tobacco Control (c1964-2014) and D. Accelerated Reduction (c2014-). These eras are very familiar to anyone steeped in tobacco history (avid readers of this column perhaps) but even so, it is very useful to name them in print. They align with the 1994 model of the cigarette epidemic in developed countries, composed of stages 1-4, with peaks and declines in smoking prevalence and (about 20 years later) associated death rates (13) . The paper presents important features that define each era. Invention and Marketing was driven by the invention of the automated cigarette machine (producing 1000s of cigarettes per hour), gentler tobacco blends that were easier to inhale and anti-trust legislation that fostered stiff competition between tobacco companies. Discovery of Harm drew upon data from momentous papers that linked smoking to lung cancer(14)(15), resisted misinformation distributed over many years by the tobacco industry and finished with the US Surgeon General's report of 1964. The Tobacco Control era introduced advertising bans, tougher government regulation and changing social norms. Social norms are mirrored best in the visual arts and can quietly and even surprisingly change. Cigarettes are everywhere in old movies and period 20 th century shows (Casablanca, Mad Men, even the odd episode of Friends). But, if you have seen the Netflix series Unorthodox (set around 2012) you will remember just two consumers of nicotine, the villain who smoked and his accomplice who vaped. Multiple important pieces of legislation mark this era including the Master Settlement Agreement (MSA) of 1998, in which 46 American states settled with four major tobacco companies to recoup over $200 billion paid over 25 years, to cover the cost of smoking-related illnesses. The MSA forced the release of internal company documents, which confirmed that the tobacco industry was aware of tobacco-related harms. It has also attracted criticism for its limitations, which include loopholes in funding commitments and redirection of payments into general state budgets (16) . In 2009 the Tobacco Control Act was passed by Congress and (finally) gave the FDA authority to regulate cigarettes. There is no big law to address vaping products in this section, perhaps because it is too soon and perhaps due to the unexpected, internet-driven manner of their arrival on the market. And where is the FCTC? The Framework Convention on Tobacco Control(1) was adopted by the WHO in 2003 and is ratified by over 180 countries, but not the United States. In the Accelerated Reduction era the tussle with the arrival of e-cigarettes and other devices (called Nicotine Vaping Products, or "NVPs") competes with the unrelenting need to help smokers overcome a severe addiction to cigarettes that are engineered specifically to maintain that addiction. Important moments during this era include a new FDA framework for tobacco regulation(17) that looked to encourage "development of innovative tobacco products that may be less dangerous than cigarettes" (ref 17, para 1). Support for this initiative came from the literature including a study that projected the saving of over 6 million lives in the US if all cigarette smokers switched to vaping products (18) . Challenges to this initiative came in the form of escalating uptake of vaping products by non-smoking adolescents, the (controversial) possibility that vaping could lead a young person towards cigarettes and from the EVALI (e-cigarette or vaping product use-associated Lung Injury) epidemic, an acute pneumonitis (19) thought to result from vitamin E acetate contamination of illicit cannabis oils. In discussion, the authors make four recommendations to help align the forces of the market with a reduction in the smoking of cigarettes, summarised as follows: 1. Embrace the risk continuum in tobacco regulation; 2. Update the tobacco control act (to cover newer products e Ed.); 3. Act nice when discussing smoking harm reduction (our words e Ed.) and 4. Scientists and manufacturers to collaborate on the development of lower risk products. This last one strikes some of our international committee members as fraught; not all of them come from countries where vaping is legal. Previous tobacco control measures (big lawsuits, big law and the response to a universal toxin) will give way to the future (newer products, complex debates about harm and a very mobile industry). "We cannot build the future by avenging the past" (20) . This paper embraces the complexities of "risk-proportionate tobacco.regulation" (ref 11, page 9, para 1). It encourages us to combine market forces (the very thing that gave the cigarette companies their global dominance) with public health. It proposes rewards for current manufacturers who invest in low risk products and finally it asks us to "reduce deaths. [from] .cigarettes in ways that were never imagined decades ago" (ref 11, p9, para 1).

WHO j WHO Framework Convention on Tobacco Control

WHO

Smoking: maintaining attention on a critical and unsolved public health problem

Tobacco smoking and all-cause mortality in a large Australian cohort study: findings from a mature epidemic with current low smoking prevalence

Mortality in relation to smoking: 50 years' observations on male British doctors

21st-Century Hazards of Smoking and Benefits of Cessation in the United States

Million Women Study Collaborators. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK

50-Year Trends in Smoking-Related Mortality in the United States

Tobacco smoking and risk of 36 cardiovascular disease subtypes: fatal and non-fatal outcomes in a large prospective Australian study

The past is not the future in tobacco control

General USPHSO of the S. Smoking and Health

A descriptive model of the cigarette epidemic in developed countries

Smoking and carcinoma of the lung; preliminary report

Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases

Tobacco control in the wake of the 1998 master settlement agreement

FDA announces comprehensive regulatory plan to shift trajectory of tobacco-related disease, death

Potential deaths averted in USA by replacing cigarettes with e-cigarettes

Vaping Associated Pulmonary Illness (VAPI)

The Once and Future King